Press Releases

Flydigi — What makes this China’s No.1 Controller Brand Stands Out

Shanghai, China - May 21, 2024 —

Flydigi, China's NO.1 gaming controller brand, has been making significant strides in gaming controller industry since 2014. Flydigi dedicated to self-development and innovation of mechanical technology, rejecting the common standard component made by the factory. Instead, Flydigi continuously reengineers every component of its controllers to meet the... (continue reading...)

Naples, Florida tops this year's list with strong desirability and job market scores.

WASHINGTON, May 21, 2024 /PRNewswire/ -- U.S. News & World Report, the global authority in rankings and consumer advice, today unveiled the 2024-2025 Best Places to Live in the U.S. The new list ranks 150 major U.S. cities based on value, desirability, job market and quality of life.

... (continue reading...)

• Releases a family of IBM Granite models into open source, including its most capable and efficient Code LLMs that can out-perform larger code models on many industry benchmarks
• Jointly with Red Hat, launches InstructLab, a first-of-its-kind model alignment technique, to bring open-source community contributions directly into LLMs
• Unveils new vision and momentum for new data and automation capabilities; Accelerates generative AI infusion into IBM assistants, automation,... (continue reading...)

Urine drug testing data reveal alarming, sustained increases in alcohol use among those with alcohol use disorder; may push higher as summer peak approaches

SAN DIEGO--(BUSINESS WIRE)-- Alcohol use increased across the U.S. during the COVID-19 pandemic but a new Millennium Health Signals Alert™ shows that it increased most dramatically among those with alcohol use disorder (AUD) and has remained elevated; up more than 20% nationally since 2019. This robust... (continue reading...)

• Findings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab[1],[2]
• Data from a post-hoc analysis of the LIBERTY-CD study showed that, despite affecting drug levels, anti-drug antibodies (ADAs) status appeared to have no significant impact on W54 clinical outcomes or discontinuation rates [3]

JERSEY CITY, N.J., May 21, 2024 /PRNewswire/ --... (continue reading...)